News

A Phase 2b/3 trial investigating the potential of SLS-005 (trehalose) to slow the progression of amyotrophic lateral sclerosis (ALS) has been added to the HEALEY ALS Platform Trial, the first such multi-regimen study created for ALS. The trial, designed by Seelos Therapeutics, the maker of…

Target ALS, a nonprofit working to advance research, has awarded a second round of grants supporting four projects that aim to discover and develop biomarkers for amyotrophic lateral sclerosis (ALS). The grants are part of The Target ALS Diagnosis Initiative, a $15 million comprehensive effort to discover…

After years of behind-the-scenes work, the ALS Association is celebrating passage of the ALS Disability Insurance Access Act of 2019, likely to end the nearly half-year wait amyotrophic lateral sclerosis (ALS) patients go through to receive Social Security Disability Insurance (SSDI) benefits. The U.S. Senate earlier this…

A single infusion of AstroRx, an off-the-shelf, investigational cell therapy for amyotrophic lateral sclerosis (ALS), safely and significantly slows disease progression in the first three months following treatment, according to updated data from an ongoing Phase 1/2 trial. These benefits waned after six months, indicating…

BrainStorm Cell Therapeutics has opened an expanded access program (EAP) in the U.S. to allow certain amyotrophic lateral sclerosis (ALS) patients to gain access to its investigational cell-based therapy NurOwn. EAPs, also known as compassionate use programs, are intended to make investigational therapies available outside of a clinical…

Researchers at QurAlis have discovered a molecule with the potential to act as a treatment for amyotrophic lateral sclerosis (ALS), in addition to a new therapeutic target for the disease. The findings from both projects were presented at the 31st International Symposium on ALS/MND,…

A method that measures tiny amounts of aggregated TDP-43 protein in the cerebrospinal fluid may have the potential to detect amyotrophic lateral sclerosis (ALS) in the early stages of the disease, potentially before symptom onset, a study reports. The study,…

Target ALS is launching an expansive $15 million research initiative aimed at discovering biomarkers and developing new scientific resources for amyotrophic lateral sclerosis (ALS). The Target ALS Diagnosis Initiative, touted as the first of its kind, will create grants and scientific resources to identify needed biomarkers. Such indicators allow…

Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic lateral sclerosis (ALS) to test its investigational therapy reldesemtiv in slowing progressive muscle weakness, the company announced. Details from the trial design were shared at the 31st International Symposium…

The anticonvulsant ezogabine can significantly reduce abnormal motor neuron excitability in people with amyotrophic lateral sclerosis (ALS), a clinical trial has found. The findings support further investigation of ezogabine, and into the possible utility of neuron excitability as a measurement of disease in ALS, researchers…